The development of positive inotropic agents for chronic heart failure: how have we gone astray?
about
The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development.Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.Chronic inotropic therapy in end-stage heart failure.Genetic manipulation of beta-adrenergic signalling in heart failure.Targeting signaling pathways in heart failure by gene transfer.The acute inotropic effects of cardiac contractility modulation (CCM) are associated with action potential duration shortening and mediated by β1-adrenoceptor signalling.GRK2 and β-arrestins in cardiovascular disease: Something old, something new.Gene therapy in heart failure.Adrenergic nervous system in heart failure: pathophysiology and therapy.GRK2 as a novel gene therapy target in heart failure.Cardiac contractility modulation in the treatment of heart failure: initial results and unanswered questions.Management of acute decompensated heart failure: treatment, controversy, and future directions.cGMP inhibition of heart phosphodiesterase: is it clinically relevant?Endogenous nitric oxide in cardiovascular disease and transplantation.Crosstalk of the heart and periphery: skeletal and cardiac muscle as therapeutic targets in heart failure.To dig or not to dig.A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy.Cardiac contractility modulation by non-excitatory currents: studies in isolated cardiac muscle.Medical management of advanced heart failure
P2860
Q30250314-5FDF0697-A1E6-496D-8858-E5FA14F213AAQ33735342-77EC57E1-3754-4385-81E7-32DF3777EE2EQ33735360-A08D30B2-8454-441E-8B52-15EF09E3FDD9Q34419016-7E26D8C3-96AF-4968-95B8-49E9696E26B3Q35095401-550F2248-A31A-46A6-BE3C-A9133450E403Q35223644-2F933CB9-9A00-48C8-B120-713AF2A9F4BCQ35660111-3CEAA88D-D7E9-489E-83EA-E17358BA8A2DQ36944623-9C760167-4596-400D-BEF7-74E7AB7A38A3Q37349756-1E81F99F-ED42-408C-8A32-89D0408CCA3BQ37783642-9C018BDD-5DD4-423A-A1F4-700C0ADACB1FQ37867850-3E4796A3-F7E2-468B-80C8-D87A03BFB891Q40304351-23594B16-265C-407A-8D3A-51C5F9CD885AQ40341857-D87027D4-887A-4365-A245-73E7BF42D46BQ40405195-752A86CE-BF4E-4013-B8AE-7C4DFA49D5FCQ41647745-B049B40F-689C-4A74-BEBF-A79C7779AA94Q42108518-0CCE98F2-D45F-4CEB-B423-870C0BE4BCE8Q44012776-D69E972C-A5CA-4BB0-8561-7E494192D8F9Q46734134-D47AF740-046B-48BC-B6C4-6A3B3B420771Q57396286-11A279FC-DDC4-462D-B4E7-47681B9B7C7B
P2860
The development of positive inotropic agents for chronic heart failure: how have we gone astray?
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
The development of positive in ...... lure: how have we gone astray?
@en
The development of positive in ...... lure: how have we gone astray?
@nl
type
label
The development of positive in ...... lure: how have we gone astray?
@en
The development of positive in ...... lure: how have we gone astray?
@nl
prefLabel
The development of positive in ...... lure: how have we gone astray?
@en
The development of positive in ...... lure: how have we gone astray?
@nl
P1476
The development of positive in ...... lure: how have we gone astray?
@en
P2093
P304
P356
10.1016/0735-1097(93)90474-F
P407
P433
P577
1993-10-01T00:00:00Z